Literature DB >> 27186714

When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH.

K Fischer1,2, P W Collins3, M C Ozelo4,5, A Srivastava6, G Young7,8, V S Blanchette9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27186714     DOI： 10.1111/jth.13298

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  13 in total

1.  Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.

Authors:  Alanna McEneny-King; Pierre Chelle; Gary Foster; Arun Keepanasseril; Alfonso Iorio; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-18       Impact factor: 2.745

2.  A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

Authors:  Guy Young; Ri Liesner; Tiffany Chang; Robert Sidonio; Johannes Oldenburg; Victor Jiménez-Yuste; Johnny Mahlangu; Rebecca Kruse-Jarres; Michael Wang; Marianne Uguen; Michelle Y Doral; Lilyan Y Wright; Christophe Schmitt; Gallia G Levy; Midori Shima; Maria Elisa Mancuso
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

Review 3.  Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.

Authors:  Massimo Morfini; Stefano Gherardini
Journal:  Ther Adv Hematol       Date:  2018-06-05

Review 4.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

Review 5.  Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.

Authors:  Pratima Chowdary
Journal:  Int J Hematol       Date:  2018-10-09       Impact factor: 2.490

6.  Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.

Authors:  Alanna McEneny-King; Pierre Chelle; Severine Henrard; Cedric Hermans; Alfonso Iorio; Andrea N Edginton
Journal:  Pharmaceutics       Date:  2017-10-17       Impact factor: 6.321

7.  Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics.

Authors:  Donna M DiMichele
Journal:  Hemasphere       Date:  2018-10-02

8.  Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).

Authors:  Alanna McEneny-King; Gary Foster; Alfonso Iorio; Andrea N Edginton
Journal:  JMIR Res Protoc       Date:  2016-12-07

9.  [Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14

10.  Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.

Authors:  Beatrice Nolan; Johnny Mahlangu; Ingrid Pabinger; Guy Young; Barbara A Konkle; Chris Barnes; Keiji Nogami; Elena Santagostino; K John Pasi; Liane Khoo; Bent Winding; Huixing Yuan; Joachim Fruebis; Dan Rudin; Johannes Oldenburg
Journal:  Haemophilia       Date:  2020-03-30       Impact factor: 4.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.